Catalyst Wire Dossier Catalyst Wire Dossier

NFC-1

· Aevi Genomic Medicine, LLC (a Cerecor company)
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for NFC-1, covering 2018-03-29 to 2025-10-21. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder [Phase 1]

See pricing